COZAAR is contraindicated in patients who are hypersensitive to any component of this product.
Significant lethality was observed in mice and rats after oral administration of 1000 mg/ kg and 2000 mg/ kg, respectively, about 44 and 170 times the maximum recommended human dose on a mg/ m 2 basis. Limited data are available in regard to overdosage in humans. The most likely manifestation of overdosage would be hypotension and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. If symptomatic hypotension should occur, supportive treatment should be instituted. Neither losartan nor its active metabolite can be removed by hemodialysis.